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Alzheimer’s disease (AD) is a clinically heterogeneous neurodegenerative disease with a strong genetic
component. Several genes have been associated with AD risk for nearly 20 years. However, it was not until
the recent technological advances that allow for the analysis of millions of polymorphisms in thousands of
subjects that we have been able to advance our understanding of the genetic complexity of AD susceptibility.
Genome-wide association studies and whole-exome and whole-genome sequencing have revealed more
than 20 loci associated with AD risk. These studies have provided insights into the molecular pathways
that are altered in AD pathogenesis, which have, in turn, provided insight into novel therapeutic targets.Alzheimer’s Disease
Alzheimer’s disease (AD) is defined clinically by a gradual decline
inmemory and other cognitive functions and neuropathologically
by gross atrophy of the brain and the accumulation of extracel-
lular amyloid plaques and intracellular neurofibrillary tangles.
Genetic, biochemical, and neuropathological data suggest
that aggregation of b-amyloid (Ab) is central to initiating AD path-
ogenesis (Hardy and Selkoe, 2002). Ab is a proteolytic fragment
of the amyloid precursor protein (APP) (Thinakaran and Koo,
2008), generated as a result of sequential cleavage by b- and
g-secretases. Deposition of extracellular amyloid plaques is
followed by the accumulation of neurofibrillary tangles in
neuronal cell bodies and associated processes (Braak and
Braak, 1991). Neurofibrillary tangles are composed of hyper-
phosphorylated tau aggregates. The presence of neurofibrillary
tangles in AD brains is strongly correlated with neuronal dysfunc-
tion and disease progression (reviewed in Holtzman et al., 2011).
The amyloid cascade hypothesis posits that changes in APP
and/or Ab homeostasis lead to the aggregation of Ab and depo-
sition in plaques and that these events are sufficient to initiate the
cascade of pathologic and clinical changes associated with AD,
including the aggregation of tau protein in neurofibrillary tangles.
Linkage Studies
Dominantly inherited mutations in b-amyloid precursor protein
(APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) cause
early-onset Alzheimer’s disease (AD). These genes as well as
APOEwere identified through genetic linkage studies in families.
APP
APP is located at chromosome 21q21 and encodes a ubiqui-
tously expressed type 1 transmembrane protein. APP is alterna-
tively spliced to produce three transcripts: APP695, APP751,
and APP770. The APP695 isoform is the major APP isoform
that is expressed in neurons, while the APP751 isoform is highly
expressed in astrocytes (Yoshikai et al., 1990). Proteolytic pro-
cessing of APP leads to the production of fragments through
the nonpathogenic and the amyloidogenic pathways. The
majority of APP is proteolyzed by a- and g-secretases, leading
to cleavage of APPwithin the Ab domain. The result is nonpatho-genic fragments: sAPPa and a-C-terminal fragment (CTF) (Thi-
nakaran and Koo, 2008). Alternatively, APP can be cleaved
through sequential proteolytic cleavage by b- and g-secretases
to generate Ab peptides, sAPPb and b-CTF. Cell-surface APP is
internalized, allowing Ab to be generated in the endocytic
pathway and secreted into the extracellular space (Thinakaran
and Koo, 2008).
Dominant mutations in APP account for approximately 14% of
early-onset autosomal dominant cases of AD (reviewed in
Guerreiro et al., 2012), with more than 30 mutations described
(http://www.molgen.vib-ua.be/ADMutations). Two recessive
APP mutations, A673V and E693D, also reportedly cause
early-onset AD (reviewed in Guerreiro et al., 2012). The majority
of mutations in APP cluster in the region that is adjacent to or
within the Ab domain; however, early genetic studies only
sequenced the exons in APP that encode the Ab sequence
(exons 16 and 17), leaving the possibility that variants may exist
elsewhere in APP that cause or increase risk for AD.
Mutations in APP have revealed many important aspects of
the molecular mechanisms underlying AD pathogenesis. The
Swedish mutation (KM670/671NL) increases plasma Ab levels
by 2- to 3-fold by altering b-secretase cleavage efficiency
(Mullan et al., 1992). Duplications of APP and the surrounding
sequence are also associated with early-onset AD. Families car-
rying these duplications exhibit classic AD and cerebral amyloid
angiopathy (CAA) (reviewed in Guerreiro et al., 2012). The fre-
quency of these copy number mutations among autosomal
dominant cases of AD varies based on the population: 18% Jap-
anese, 8% French, 2% Dutch, but none in Swedish/Finnish
early-onset familial cases (reviewed in Guerreiro et al., 2012).
Additionally, individuals with Down syndrome, which results
from trisomy of chromosome 21, develop AD neuropathology
(reviewed in Guerreiro et al., 2012). Individuals with partial tri-
somy of chromosome 21, which does not include the APP
gene, fail to develop AD neuropathology (reviewed in Guerreiro
et al., 2012). Thus, excess Ab production is sufficient to cause
AD. Several APP mutations cluster at or after the C-terminal
portion of the Ab domain. These mutations alter g-secretase
function, leading to a shift in APP processing that increasesNeuron 83, July 2, 2014 ª2014 Elsevier Inc. 11
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fragment. The result is an altered Ab42/Ab40 ratio without a
change in total Ab levels (Bergmans and De Strooper, 2010).
Because Ab42 is more prone to aggregate than Ab40, these
findings suggest that Ab aggregation is a critical component of
AD pathogenesis. The Arctic mutation (E693G) occurs within
the Ab domain (reviewed in Guerreiro et al., 2012). While this
mutation fails to alter absolute Ab levels or the Ab42/Ab40 ratio,
the Arctic mutation probably increases the aggregation rate of
the mutant peptide (Nilsberth et al., 2001). The Dutch mutation
(E693Q) also occurs in the Ab domain and reportedly results in
accelerated Ab aggregation (reviewed in Guerreiro et al., 2012).
Individuals carrying the Dutch mutation develop hereditary cere-
bral hemorrhage with amyloidosis, which is characterized by
predominant vascular Ab deposition with diffuse plaques in the
parenchymal tissue (reviewed in Guerreiro et al., 2012). These
mutations provide further evidence that Ab aggregation is a crit-
ical process in AD pathogenesis. Genetic changes that lead to
altered APP processing and Ab accumulation may produce var-
iable neurological and neurovascular phenotypes.
PSEN1 and PSEN2
PSEN1 is located at chromosome 14q24.3, while its
homolog, PSEN2, is located at chromosome 1q31-q42. PSEN1
and PSEN2 are structurally similar integral membrane proteins
that contain nine transmembrane domains with a hydrophilic
intracellular loop region (reviewed in Guerreiro et al., 2012).
PSEN1 and PSEN2 are critical components of the g-secretase
complex, which cleaves APP into Ab fragments. PSEN1 and
PSEN2 localize in the endoplasmic reticulum and Golgi appa-
ratus, where they play an important role in protein processing
(De Strooper, 2003; Kovacs et al., 1996). As many as 185 domi-
nant, pathogenic mutations have been identified in PSEN1, ac-
counting for approximately 80% of early-onset familial AD cases
(reviewed in Guerreiro et al., 2012) (http://www.molgen.vib-ua.
be/ADMutations). To date, 13 dominant, pathogenic mutations
have been identified in PSEN2, which account for approximately
5% of early-onset, familial AD cases (reviewed in Guerreiro et al.,
2012) (http://www.molgen.vib-ua.be/ADMutations). PSEN1 and
PSEN2 mutations are distributed throughout the protein, with
some clustering occurring in the transmembrane domains (Guer-
reiro et al., 2010). Dominantly inherited mutations in PSEN1, as
well as APP, have also been identified in late-onset AD cases
with a strong family history of disease (see discussion below).
These families may carry additional genetic variants that delay
age at onset of the normally fully penetrant disease mutation.
Additional variants have been described in PSEN1 and PSEN2
that are nonpathogenic or whose pathogenicity remains unclear.
Recent evidence suggests that some of these variants, such as
PSEN1 E318G (Benitez et al., 2013) and PSEN2 R62H (Cruchaga
et al., 2012a), may represent risk factors for AD (described
below).
PSEN1 and PSEN2 with nicastrin, anterior pharynx-defective-
1 (APH-1), and presenilin enhancer 2 (PEN2) form the g-secre-
tase complex, which catalyzes the cleavage of many membrane
proteins (Wakabayashi and De Strooper, 2008). Elegant kinetic
studies by Cha´vez-Gutie´rrez and colleagues have demonstrated
that familial AD mutations in PSEN1 and PSEN2 affect g-secre-
tase function by three mechanisms (Cha´vez-Gutie´rrez et al.,12 Neuron 83, July 2, 2014 ª2014 Elsevier Inc.2012). First, there are variable inhibitory effects on the initial
endoproteolytic cleavage step that releases the intracellular
domain of APP. Second, there is a premature release of interme-
diary substrates of APP during the consecutive carboxypepti-
dase-like g-secretase cleavage, leading to the generation of
longer Ab peptides. Finally, there is an effect on the cleavage
site, leading to preferential cleavage of APP at position 49–50
or 51–50. These three mechanisms provide an explanation of
the historical observations that PSEN1 and PSEN2 mutations
lead to altered Ab42/Ab40 ratios.
ADAM10
Recently, rare coding variants in ADAM10 were found to cose-
gregate in seven late-onset AD families (Kim et al., 2009b).
ADAM10 is the major a-secretase involved in cleavage of the
APP ectodomain (Jorissen et al., 2010; Kuhn et al., 2010; Postina
et al., 2004). ADAM10 risk variants, Q170H and R181G, increase
Ab levels in vitro (Kim et al., 2009b). In Tg2576 mice, ADAM10
Q170H and R181G disrupt a-secretase activity and shift APP
processing toward amyloidogenic cleavage, yielding increased
plaque load (Suh et al., 2013). These genetic and biological find-
ings provide further support for the hypothesis that alteration of
APP processing and Ab generation is sufficient to cause AD.
APOE
Apolipoprotein E (APOE) is located at chromosome 19q13.2 and
encodes a pleiotropic glycoprotein. APOE is highly expressed in
liver, brain, andmacrophages (Siest et al., 1995), where it plays a
role in mobilization and redistribution of cholesterol (Mahley,
1988). APOE has also been implicated in neuronal growth and
repair, nerve regeneration, immune response, and activation of
lipolytic enzymes (Mahley, 1988; Mahley and Rall, 2000). APOE
occurs as three possible isoforms that differ based on two amino
acid residues (112 and 158): APOEε2, APOEε3, and APOEε4.
APOEε3 is the most common APOE isoform, occurring in
approximately 72% of the population. Family-based methods
originally identified genetic linkage between AD and the region
of chromosome 19 that contains the APOE gene (reviewed in
Guerreiro et al., 2012). APOEε4 increases risk in familial and spo-
radic early- and late-onset AD, increasing risk 3-fold for hetero-
zygous carriers and increasing risk 8- to 10-fold for homozygous
carriers (reviewed in Guerreiro et al., 2012). APOEε4 also has a
dose-dependent effect on age at onset. Interestingly, APOEε2
decreases risk for late-onset AD and delays age at onset
(reviewed in Guerreiro et al., 2012). Rare coding variants that
affect risk for AD may also occur in APOE (Kamboh et al.,
1999; Medway et al., 2014); however, deep sequencing of the
APOE gene in large data sets has not been performed. It is
also possible that APOE variants exist in regulatory regions
that impact APOE expression, which could, in turn, influence
plaque accumulation. In mousemodels, APOE expression levels
influence amyloid plaque accumulation (Kim et al., 2011a).
The role of APOE in AD is complex. APOE binds to Ab, influ-
encing the clearance of soluble Ab and Ab aggregation (Castel-
lano et al., 2011; Kim et al., 2009a). APOE4 binds to Ab more
rapidly than APOE3, resulting in accelerated fibril formation
(Sanan et al., 1994; Strittmatter et al., 1993). APOE also regulates
Ab metabolism indirectly by interacting with low-density lipo-
protein receptor-related protein 1 receptors (Verghese et al.,
2013). In vivo, APOE influences the amount and structure of
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(Fagan et al., 2002; Holtzman et al., 2000). Thus, the major risk
gene associated with AD probably influences Ab metabolism
as a mechanism of pathogenicity.
Genome-Wide Association Studies
Case/Control Studies
Only 50% of individuals with AD carry an APOEε4 allele, sug-
gesting that other genetic factors must contribute to risk for
disease. Before 2005, the general strategy used to identify
novel risk genes was to perform an analysis of one or more
polymorphisms in a candidate gene. Despite hundreds of
studies, few reported genetic associations were replicated
across studies, most likely due to type 1 error (false-positive as-
sociations in the discovery data set) (see http://www.alzgene.
org) (Bertram et al., 2010). The main reason for this is that other
common genetic risk factors probably have a much smaller
impact on risk than APOE. As a result, these studies lacked
power to detect novel risk genes because the sample sizes
used in earlier studies were too small. Since 2005, several tech-
nological advances have transformed studies of the genetics of
complex traits such as AD (Wray et al., 2008). The first advance
was the development of cheap and comprehensive genome-
wide arrays, allowing for the simultaneous evaluation of millions
of SNPs in thousands of samples, genome-wide association
studies (GWASs). The first GWAS for AD used modest sample
sizes (500–2,000 samples) and most studies only detected
genome-wide significant evidence of association for APOE
(reviewed in Bertram et al., 2010). The first studies to use
thousands of AD cases and elderly nondemented controls suc-
cessfully generated replicable associations for several new
genetic risk factors including clusterin (CLU), phosphatidylinosi-
tol-binding clathrin assembly protein (PICALM), complement re-
ceptor 1 (CR1), bridging integrator protein 1 (BIN1), and sialic
acid–binding immunoglobulin (Ig)–like lectin (CD33) (Bertram
et al., 2008; Harold et al., 2009; Lambert et al., 2009; Seshadri
et al., 2010) (Table 1). Two subsequent studies that each
included more than 8,000 cases and a similar number of con-
trols identified additional loci with genome-wide significant
evidence for association (<5 3 108): membrane-spanning 4A
gene cluster (MS4A4A, MS4A6A, MS4A6E), CD2-associated
protein (CD2AP), Ephrin receptor A1(EPHA1), and ATP-binding
cassette transporter (ABCA7) (Hollingworth et al., 2011; Naj
et al., 2011) (Table 1).
Several studies have now demonstrated a clear relationship
between the size of the study and the number of genome-wide
significant signals across a range of traits (Ball, 2013; Lambert
et al., 2013). Recently, a meta-analysis of GWAS data from
74,046 individuals from four large consortia confirmed all of the
previous associations except CD33 and reported 12 new
susceptibility loci for AD. The signals are close to the genes:
Cas scaffolding protein family member 4 (CASS4), CUGBP,
Elav-like family member 1 (CELF1),Desmoglein 2 (DSG2), Fermi-
tin family member 2 (FERMT2),Major histocompatibility complex
class II,DR beta 5-1 (HLA-DRB5-DRB1), Inositol polyphosphate-
5-phosphatase (INPP5D),myocyte enhancer factor 2C (MEF2C),
NME/NM23 family member 8 (NME8), Protein tyrosine kinase 2
beta (PTK2B), solute carrier family 24 (SLC24A4)-Ras and rab in-teractor 3 (RIN3), sortilin-related receptor L, A repeats containing
(SORL1), zinc finger, and CW type with PWWP domain 1
(ZCWPW1) (Lambert et al., 2013) (Table 1). However, as of today,
it is not clear whether variants in these genes or neighboring
genes are responsible for the initial association. It is likely that
as sample sizes continue to grow, additional risk loci will be
revealed. However, until those studies are performed, it is diffi-
cult to predict which GWAS signals with p values greater than
108 will be ‘‘real’’ AD risk genes.
These studies employed samples of European descent but
two additional GWASs have examined African-American and
Asian (Korean and Japanese) case-control series. In addition
to APOE, the most significant finding in the African-American
study of 5,896 cases and controls was with SNPs in ABCA7,
which reached genome-wide significance and exhibited a
somewhat larger effect than in European samples (Reitz
et al., 2013). Other loci seen in Europeans showed p values <
0.05 (BIN1, CR1, EPHA1, and CD33). The study in Japanese
and Koreans used a multistage strategy to identify a novel
locus, SORL1, which was replicated in a large European
American cohort (Lambert et al., 2013; Miyashita et al., 2013).
PICALM and BIN1 SNPs also showed association in the Asian
case-control series. Together, these studies demonstrate that
some of these loci show similar effects across populations
(e.g., BIN1), while others appear to have a bigger impact in
some populations (e.g., ABCA7). As larger data sets become
available for other populations, population-specific loci and
those that are shared across populations will become more
fully resolved.
The common SNPs identified in these GWASs alter risk by
10%–15%, suggesting that the effect of these risk alleles is
much smaller than that of APOEε4 unless they are tagging rare
alleles of larger effect. For the most part, the functional alleles
responsible for each of these associations remain to be deter-
mined. For some of the GWAS loci, there are several genes
within the associated region, any one of which may contain the
functional risk variant (see Table 1). However, many of these
AD risk loci have putative functions in the immune system
(CLU, CR1, ABCA7, CD33, and EPHA1); four are involved in
processes at the cell membrane, including endocytosis
(PICALM, BIN1, CD33, and CD2AP); and three are involved in
lipid biology (APOE, CLU, and ABCA7) (Table 1; Figure 1).
Although some of the new genes appear to be involved in Ab
metabolism (for example, CLU and PICALM), the fact that others
probably influence inflammation, endocytosis, and lipid biology
suggests that targeting specific components of these pathways
may lead to novel directions for drug discovery and treatment. It
is also possible that some of the new genetic discoveries are not
targeting the nearby gene but actually targeting noncoding
RNAs. If so, this could also provide new insights.
Approaches for identifying new risk factors associated with
other aspects of the late-onset AD phenotype include genetic
studies for elucidating the rate of disease progression, age at
onset, cerebrospinal fluid (CSF) or plasma biomarker measure-
ments, and functional and structural imaging measures.
Neuroimaging
Genetic studies using twin and family-based designs have
demonstrated that many brain-derived traits, includingNeuron 83, July 2, 2014 ª2014 Elsevier Inc. 13
Table 1. Functional Classes of AD Genes
SNP Gene MAF
Odds
Ratio Known Function
Related AD
Risk Genes
Potential Effects
on APP and Tau Pathways
Gene
Expression
– APP – – Neurite outgrowth, adhesion,
and axonogenesis
– Cleavage yields
Ab
APP processing –
– PSEN1 – – Component of catalytic
subunit of gamma-secretase
complex; proteolytic
cleavage of integral
membrane proteins
– Cleaves APP APP processing –
– PSEN2 – – Component of catalytic
subunit of gamma-secretase
complex; proteolytic
cleavage of integral
membrane proteins
– Cleaves APP APP processing –
– APOE – – Mediates binding,
internalization, and
catabolism of
lipoproteins
SORL1 Ab clearance Lipid metabolism –
– ADAM10 – – Proteolytic cleavage
of integral membrane
proteins
– Cleaves APP APP processing –
rs6656401 CR1a 0.197 1.18 Mediates cellular
binding of immune
complexes that
activate complement
– Ab clearance Immune Response Increased
rs6733839 BIN1b 0.409 1.22 Regulation of endocytosis
of synaptic vesicles
SLC24A4
and RIN3
Mediates tau
toxicity
Synapse function Increased
rs10948363 CD2AP 0.266 1.1 Scaffold molecule
regulating actin
cytoskeleton
INPP5D
and CASS4
Mediates tau
toxicity
Synapse function
and endocytosis
No change
rs11771145 EPHA1c 0.338 0.9 Brain and neural
development; angiogenesis,
cell proliferation,
and apoptosis
– – Immune response
and neural
development
No change
rs9331896 CLU 0.379 0.86 Chaperone; regulation
of cell proliferation
PTK2B Ab clearance Immune response
and lipid
metabolism
Increased
rs983392 MS4A6Ad 0.403 0.9 Signal transduction – – Immune response No change
rs10792832 PICALMe 0.358 0.87 AP2-dependent
clathrin-mediated
endocytosis
– APP trafficking
and Ab clearance
Synapse function
and endocytosis
No change
rs4147929 ABCA7f 0.19 1.15 Lipid homeostasis;
phagocytosis of apoptotic
cells by macrophages
– Ab clearance Immune response
and lipid
metabolism
Increased
rs3865444 CD33 0.307 0.94 Mediates sialic
acid-dependent
binding to cells
– Ab clearance Immune response Increased
rs9271192 HLA-DRB5–
HLA-DRB1g
0.276 1.11 Immunocompetence
and histocompatibility
– – Immune response –
rs28834970 PTK2B 0.366 1.1 Induction of long term
potentiation in
hippocampus
CLU – Synapse function
and neural
development
–
rs11218343 SORL1 0.039 0.77 APOE receptor; binds LDL
and RAP and mediates
endocytosis of the lipids
to which it binds
APOE APP trafficking Lipid metabolism,
synapse function,
and endocytosis
Decreased
(Continued on next page)
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Table 1. Continued
SNP Gene MAF
Odds
Ratio Known Function
Related AD
Risk Genes
Potential Effects
on APP and Tau Pathways
Gene
Expression
rs10498633 SLC24A4
and RIN3
0.217 0.91 Brain and neural
development (SLC24A4);
stimulates and stabilizes
GTP-Rab5 in protein
transport from plasma
membrane to early
endosome (RIN3)
BIN1 – Neural development,
synapse function,
and endocytosis
–
rs8093731 DSG2h 0.017 0.73 Mediates cell-cell junctions
between epithelial and
other cell type
– – – –
rs35349669 INPP5D 0.488 1.08 Negative regulator of
myeloid cell proliferation
and survival
CD2AP – Immune response –
rs190982 MEF2C 0.408 0.93 Controls synapse formation
during activity-dependent
refinement of synaptic
connectivity and facilitates
hippocampal-dependent
learning and memory
– – Neural development,
synapse function,
and immune
response
–
rs2718058 NME8i 0.373 0.93 Ciliary functions – – – –
rs1476679 ZCWPW1
and NYAP1j
0.287 0.91 Epigenetic regulation
(ZCWPW1); brain and
neural development (NYAP1)
– – Neural
development
–
rs10838725 CELF1
and MADDk
0.316 1.08 Regulates pre-mRNA
splicing (CELF1); long-term
neuronal viability (MADD)
– Mediates tau
toxicity
Neural
development
–
rs17125944 FERMT2 0.092 1.14 Actin assembly and cell
shape and mediator of
angiogenesis
– Mediates tau
toxicity
Cytoskeleton and
axonal transport
–
rs7274581 CASS4l 0.083 0.88 Docking protein in
tyrosine-kinase signaling
involved in cell adhesion
and spreading
CD2AP – Cytoskeleton and
axonal transport
–
rs75932628 TREM2 0.049 2.55 Immune response, triggers
production of inflammatory
cytokines
– Ab clearance Immune response –
rs145999145 PLD3 0.06 2.75 Unknown – APP trafficking
and cleavage
Unknown Increased
aCR2, CR1L also located within GWAS locus.
bCYP27C1 also located within GWAS locus.
cLOC285965, TAS2R60 also located within GWAS locus.
dMS4A3, MS4A2, MS4A6A, MS4A4A, MS4A6E also located within GWAS locus.
eEED also located within GWAS locus.
fCNN2, POLR3E, GPX4 also located within GWAS locus.
gHLA-DRB6, HLA-DQA1, HLA-DQB1also located within GWAS locus.
hGSG2 also located within GWAS locus.
iGPR141 also located within GWAS locus.
jPMS2P1, PILRB, PILRA, C7ORF61, C7ORF47, MEPCE also located within GWAS locus.
kSLC39A13, PSMC3, NDUFS3, KBTBD4, PTPMT1, MTCH2, AGBL2, FNBP4, NUP160 also located within GWAS locus.
lC20ORF43, CSTF1 also located within GWAS locus.
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heritable (Koten et al., 2009; Thompson et al., 2001). Imaging
phenotypes have been used for gene discovery using GWAS
approaches and to better understand the phenotypes associ-
ated with known genetic risk factors.The most widely studied candidate gene in imaging studies of
AD is APOE. APOEε4 carriers demonstrate accelerated loss of
gray matter with age (Lu et al., 2011), decreased connectivity
in the default mode network (Damoiseaux et al., 2012), increased
hippocampal atrophy (Potkin et al., 2009), increased amyloidNeuron 83, July 2, 2014 ª2014 Elsevier Inc. 15
Figure 1. Cell-Type Expression of Alzheimer’s Disease Risk Genes
May Influence AD Pathogenesis
The major cell types present in the brain are depicted. Genes are listed in the
cell type in which they are most highly expressed (B. Barres, personal
communication). GWAS loci that contain multiple genes were excluded from
this figure, as it remains unclear which gene is responsible for the signal (CR1,
BIN1, PICALM, HLA, SLC24A4, DSG2, ZCWPW1, CELF1, FERMT2, CASS4).
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ust et al., 2012; Ramanan et al., 2014), decreased glucose meta-
bolism (Reiman et al., 2005), and increased numbers of cerebral
microbleeds, associated with higher levels of cerebral amyloid
angiopathy (Yates et al., 2014). Several studies have shown dif-
ferences in brain structure and metabolism among individuals
carrying APOEε4 (Chen et al., 2010; Schraml et al., 2013) and
other AD risk alleles in cognitively normal adults decades before
the onset of AD (Biffi et al., 2010; Bralten et al., 2011; Braskie
et al., 2011; Erk et al., 2011; Rajagopalan et al., 2013). The
late-onset AD GWAS SNP in BIN1 has been associated with en-
torhinal cortex thickness (Biffi et al., 2010), while GWAS SNPs in
CR1 have been associated with brain amyloid burden (Thambi-
setty et al., 2010) and episodic memory decline in healthy and
cognitively impaired elders (Keenan et al., 2012), and several
PICALM SNPs were associated with entorhinal cortex thickness
(Biffi et al., 2010; Furney et al., 2011). The Alzheimer’s disease
Neuroimaging Initiative (ADNI) has made both imaging and ge-
netic data publicly available on 1,650 individuals. As a result,
more than 100 genetic studies have been published using this
data (reviewed in Shen et al., 2014). A recent GWAS of florbetapir
PET signal reported genome-wide significant association with
APOE and butyryl cholinesterase (BCHE) SNPs, previously asso-
ciated with BCHE activity (Ramanan et al., 2014). GWAS of hip-
pocampal atrophy implicated additional risk genes, such as
FRMD6 (Shen et al., 2014), that have subsequently been shown
to be associated with disease in AD cohorts (Hong et al., 2012;
Sherva et al., 2014), demonstrating the value of using these
endophenotypes to augment genetic studies. The Enhancing16 Neuron 83, July 2, 2014 ª2014 Elsevier Inc.Neuroimaging Genetics through Meta-Analysis (ENIGMA) Con-
sortium was formed in 2009 to enhance the replicability of
GWAS findings for neuroimaging phenotypes (Thompson et al.,
2014). Together with the CHARGE consortium, this group has
meta-analyzed tens of thousands of individuals with GWAS
and MRI scans. These meta-analyses have provided compelling
evidence for novel loci influencing hippocampal volume and
intracranial volume (Stein et al., 2012).
Fluid Biomarkers
Several studies have examined the genetics of both plasma and
cerebrospinal fluid biomarkers. Most studies have focused on
Ab or tau/ptau, two well-studied and validated AD biomarkers
(reviewed in Craig-Schapiro et al., 2009). Like the case-control
studies, early biomarker studies examined candidate genes
and found strong evidence for association between CSF Ab
and APOE genotype, providing further evidence that APOE influ-
ences AD through an Ab-dependent mechanism (Kauwe et al.,
2009; Kim et al., 2011b). Several other candidate genes from
case-control GWAS have been examined in the fluid biomarker
data sets, e.g., variants in SORL1, CLU, and MS4A4A have
been associated with CSF Ab levels (Alexopoulos et al., 2011;
Elias-Sonnenschein et al., 2013), while others found no evidence
for association (Kauwe et al., 2011). Subsequent studies have
taken a genome-wide approach. However, GWAS of CSF Ab
have not observed genome-wide significant evidence of asso-
ciation for any locus other than APOE (Kim et al., 2011b). This
suggests that APOE genotype explains a large proportion of
the variance in Ab levels and that no other loci have similarly large
effects. It is also likely that some of the problems in these
analyses may be due to measurement problems for the Ab
phenotype (reviewed in Mattsson et al., 2013). A recent GWAS
of plasma Ab in over 3,500 individuals failed to observe any
genome-wide significant signals including APOE (Chouraki
et al., 2014). It is unclear whether this reflects differences in sys-
temic versus CNS regulation of Ab levels byAPOE or evidence of
differences in measurement of Ab across studies that can
decrease the power of a meta-analysis or both.
In contrast, CSF tau/phospho-tau studies have demonstrated
some success. Initial studies using a candidate gene approach
reported association between phospho-tau 181/total tau and
SNPs inPPP3R1, the regulatory subunit of calcineurin (Cruchaga
et al., 2010). The same SNPs were reported to be associated
with rate of cognitive decline in this study (Cruchaga et al.,
2010) and in an independent cohort (Peterson et al., 2014).
Several studies have also reported association between MAPT
SNPs and CSF tau levels (Kauwe et al., 2008; Laws et al.,
2007). Initial GWAS of CSF tau levels reported association with
the APOE region of chromosome 19 but did not identify novel
associations at a genome-wide significant level (Han et al.,
2010; Kim et al., 2011b). The largest published CSF GWAS
examined 1,269 individuals and reported four genome-wide sig-
nificant loci in APOE, between GEMC1 and OSTN on chromo-
some 3, at 9p24.2 within GLIS3 and at 6p21.1 within the TREM
gene cluster (Cruchaga et al., 2013). The APOE association
with CSF tau levels was significant even after inclusion of CSF
Ab levels as a covariate, suggesting that APOE genotypemay in-
fluence tau levels by both Ab-dependent and Ab-independent
mechanisms. SNPs in APOE and those between GEMC1 and
Neuron
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and rate of cognitive decline (Cruchaga et al., 2013). Cell and
animal studies provide some support for Ab-independent effects
of APOE on tau metabolism (Mahley and Huang, 2012; Wolf
et al., 2013).
While Ab and tau are the most well studied AD fluid bio-
markers, several other proteins implicated in AD GWASs have
also been examined in genetic studies of AD endophenotypes
including CSF and plasma levels of APOE and CLU. SNPs in
CLU associated with AD risk were also associated with clusterin
protein levels in plasma in several studies (Schu¨rmann et al.,
2011; Xing et al., 2012). CSF APOE levels appear to exhibit
strong genetic control with 72% of the variability in CSF APOE
levels explained by SNPs on a GWAS chip (Cruchaga et al.,
2012b). The single largest effect was explained by APOEε4 ge-
notype, which explained 8% of the variance. No other genetic
variant reached the genome-wide significance threshold, but
nine additional variants exhibited a p value < 106. Pathway anal-
ysis indicated that these loci are involved in lipid metabolism.
Sequencing Studies
Themost recent GWAS for late-onset AD combined several large
data sets and identifiedmore than 20 loci associated with AD risk
(Lambert et al., 2013). However, each of these new loci only
account for a small percentage of the genetic variance that con-
tributes to AD susceptibility. Thus, a large proportion of the ge-
netic heritability for AD has not been explained by GWAS.
It has been hypothesized that low-frequency (MAF 1%–5%)
and rare variants (MAF < 1%) may explain the missing genetic
heritability. As was the case with linkage and GWAS, initial
sequencing efforts were focused on candidate genes in small
populations until the arrival of next-generation sequencing tech-
nology, which allowed for low-cost, high-throughput sequencing
and ushered in the era of whole-exome and whole-genome
sequencing. Even with these new advances, the first studies
using this technology were also focused on the pathogenic AD
genes. Subsequent genome-wide studies led to the identifica-
tion of novel variants and genes.
One powerful approach to identify AD risk variants with large
effect sizes has been to study families with a strong history of
late-onset AD. Studies sponsored both by NIMH and by NIA
have invested in the collection and characterization of large
family data sets with at least two late-onset AD cases (Wijsman
et al., 2011; Bertram et al., 2008).
Resequencing of Pathogenic AD Genes
Although pathogenic mutations in APP, PSEN1, and PSEN2
were originally associated with early-onset, familial AD, muta-
tions in these genes have also been reported in families with
late-onset AD (Devi et al., 2000; Jayadev et al., 2010; Kauwe
et al., 2007; Larner et al., 2007; Tomaino et al., 2007). Mutation
screening efforts in APP have been historically limited to exons
16 and 17 in early-onset AD families (reviewed in Guerreiro
et al., 2012). Screening for APP mutations in exons 16–17 in 40
late-onset AD families identified one pathogenic APP mutation
(E693G) with incomplete penetrance in a single family (reviewed
in Guerreiro et al., 2012). Screening for mutations in PSEN1 has
been performed mainly in early-onset AD families, although a
small number of late-onset AD cases (>60 years; <100 families)were also screened leading to the report of some late-onset
AD families carrying mutations in PSEN1 (Arango et al., 2001;
de Silva et al., 2001; Devi et al., 2000; Kauwe et al., 2007; Larner
et al., 2007; Rogaeva et al., 2001; Scacchi et al., 2007; Taddei
et al., 2002).
No systematic screen of APP, PSEN1, and PSEN2 in late-
onset AD families was published until 2012. Twelve missense,
nonsense, and splice-site variants were found in 28 families
(6.3% of the screened families), including known pathogenic
variants in PSEN1 in seven families (Cruchaga et al., 2012a).
Likely pathogenic variants, defined as novel variants that segre-
gated with disease status, were found in APP. Similar results
were reported in an Ibero-American cohort (Jin et al., 2012),
where two known and one novel likely pathogenic mutation in
PSEN1were found in three of 176 cases. Together, these studies
suggest that the impact of mutations inAPP,PSEN1, andPSEN2
in late-onset AD families is higher than previously estimated,
affecting between 1.5% and 2% of all AD families.
Protective APP Variants
It is well known thatAPOEε4 is associated with increased AD risk
and thatAPOEε2 decreases AD risk, demonstrating that different
variants within the same gene may have opposing effects on
disease risk. However, most genetic studies of AD have focused
on identifying variants that increase AD risk. In fact, until recently,
no study had reported a protective variant in APP, PSEN1, or
PSEN2. Jonsson et al. reported that rs63750847 (APP A673T)
was associated with reduced risk for AD (odds ratio [OR] =
0.23) in the Icelandic population (Jonsson et al., 2012). Interest-
ingly, this mutation occurs at the same amino acid residue as a
recessive mutation reported to cause early-onset AD (APP
A673V) (Di Fede et al., 2009). This mutation is near the proteolytic
cleavage site of BACE1 (position 2 in the Ab peptide) and results
in impaired BACE1 cleavage of APP in the A673T carriers and
reduction of Ab40 and Ab42 in vitro (Jonsson et al., 2012). This
study provides a proof of principle for the hypothesis that
reducing the BACE1 cleavage of APP may protect against AD.
Risk Variants in APP, PSEN1, and PSEN2
In addition to identifying known and likely pathogenic mutations
in APP and PSEN1, the resequencing studies have revealed
additional variants that may modify AD risk. Thus far, all of the
genetic variants in these genes have been classified as patho-
genic or not pathogenic. However, it is likely that rare variants
in APP, PSEN1, and PSEN2 could also act as risk factors for
AD. For example, the PSEN2 variants, R62H and R71W, failed
to show perfect segregation with AD status but were found to
be associated with a lower age at onset. The hypothesis that
variants in APP, PSEN1, and PSEN2 may serve as risk factors
for AD is further supported by a later study in which next-gener-
ation sequencing technologies and biomarker levels were com-
bined to identify additional risk variants (Benitez et al., 2013).
PSEN1 E318G (rs17125721) was previously classified as
nonpathogenic because it does not segregate with disease
status in some families (Lindquist et al., 2009; Sandbrink et al.,
1996). This coding variant was strongly associated with CSF
total Tau and pTau181 levels (Benitez et al., 2013). Analyses in
case-control series demonstrated that in APOEε4 carriers,
PSEN1-E318G is associated with a 10-fold increase in risk of
developing AD and an earlier age at onset of AD (Benitez et al.,Neuron 83, July 2, 2014 ª2014 Elsevier Inc. 17
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PSEN1 and PSEN2 are risk factors for AD rather than fully pene-
trant, causative mutations.
The identification of novel variants in genes that are associated
with disease may present as a challenge in the clinic. Several
groups have developed guidelines for determining whether a
novel variant is truly pathogenic (Guerreiro et al., 2010). These
guidelines examine segregation and association data. Variants
that occur in three or more cases in a single family are classified
as pathogenic. Variants occurring in two cases in a single family
are probably pathogenic. For variants identified in only one case,
variants are classified as probable if present in three cases and
absent in at least 100 controls, possible if present in two cases
and absent in at least 100 controls, and not pathogenic/risk
factor if present in controls. Probable pathogenicity is further
confirmed by demonstration of conservation between PSEN1
and PSEN2, presence of pathogenic mutations at the same res-
idue, fitting the helix rule, and altering Ab levels.
Impact of Dementia Genes in Clinical AD
Mutations in progranulin (GRN), microtubule-associated protein
tau (MAPT), and the hexanucleotide expansion repeat in
C9ORF72 are established causes of familial frontotemporal de-
mentia (FTD) (DeJesus-Hernandez et al., 2011; Huey et al.,
2006; Van Deerlin et al., 2007). However, several studies have
reported individuals carrying these mutations presenting with
clinical symptoms that are indistinguishable from AD (Brouwers
et al., 2007; Cortini et al., 2008; Kelley et al., 2010; Lindquist et al.,
2008; Ludolph et al., 2009; Momeni et al., 2009; Rademakers
et al., 2003, 2007; Reed et al., 1997). Among those that have
come to autopsy, all had a confirmed diagnosis of FTD. Recent
studies in which these genes were screened in large clinical
series of AD cases suggest that the frequency of pathogenic
mutations in GRN, MAPT, and C9ORF72 in clinical AD is similar
to the frequency of pathogenic mutations in APP, PSEN1, and
PSEN2 (Cruchaga et al., 2012a; Jin et al., 2012; Wojtas et al.,
2012). Overall, more than 67 GRN and MAPT mutation carriers
with AD-like symptoms of dementia have been described
(Brouwers et al., 2007, 2008; Carecchio et al., 2009; Cortini
et al., 2008; Kelley et al., 2010; Lindquist et al., 2008, 2009;
Momeni et al., 2009; Ostojic et al., 2004; Rademakers et al.,
2003, 2007; Tolboom et al., 2010), 80% of which have a clear
family history of dementia and 72% showed an age at onset
R60 years. These data suggest that there is substantial hetero-
geneity in the clinical presentation associated with FTD muta-
tions and that clinical cohorts of AD are frequently contaminated
with cases of FTD misdiagnosed as AD.
New AD Risk Genes: TREM2
Usingwhole-exome sequencing andwhole-genome sequencing
strategies, two groups simultaneously reported a low-frequency
variant (TREM2 R47H; rs75932628) in triggering receptor ex-
pressed on myeloid cells 2 protein (TREM2) that was associated
with an increase in AD risk (Guerreiro et al., 2013a; Jonsson et al.,
2013).While there has been some disagreement as to the degree
to which TREM2 R47H increases AD risk, a meta-analysis of all
of the reports describing an association between TREM2 R47H
and risk for AD reported that carrying the TREM2 R47H variant
increases risk for AD by 3.4-fold (Guerreiro and Hardy, 2013).
Guerreiro et al. described several rare variants in TREM2 that18 Neuron 83, July 2, 2014 ª2014 Elsevier Inc.were observed more frequently in cases than controls, suggest-
ing that there may be multiple rare variants in TREM2 that
increase risk for AD. This is supported by a recent study showing
that TREM2 R47H and TREM2 R62H are associated with AD risk
(Cuyvers et al., 2014). Several studies also suggest that TREM2
R47H could be associated with Parkinson’s disease, frontotem-
poral dementia, and amyotrophic lateral sclerosis (Guerreiro
et al., 2013b; Lattante et al., 2013; Rayaprolu et al., 2013), but
this remains controversial. In previous studies, rare homozygous
loss-of-function mutations in TREM2 were associated with an
autosomal recessive form of early-onset dementia, polycystic
lipomembranous osteodysplasia with sclerosing leukoencephal-
opathy (PLOSL) (Paloneva et al., 2003). Subsequent studies
found TREM2 mutations in three patients with frontotemporal-
like dementia without any bone-associated symptoms (Guer-
reiro et al., 2013b). These observations highlight a recurring
theme in neurodegenerative diseases: that heterozygous and
homozygous mutations in the same gene can lead to clinically
distinct disorders (Hruska et al., 2008; Singleton et al., 2010;
Smith et al., 2012; Swan and Saunders-Pullman, 2013).
TREM2 is a type one transmembrane receptor protein ex-
pressed on myeloid cells including microglia, monocyte-derived
dendritic cells, osteoclasts, and bone-marrow-derived macro-
phages (reviewed in Colonna, 2003). TREM2 transduces its intra-
cellular signaling through TYROBP. Although the natural ligands
of TREM2 remain speculative, upon ligand binding TREM2 asso-
ciates with TYROBP to mediate downstream signaling. In the
brain, TREM2 is primarily expressed on microglia and has
been shown to control two signaling pathways: regulation of
phagocytosis and suppression of inflammation reactivity
(reviewed in Colonna, 2003). The identification of coding variants
in TREM2 that increase risk for AD supports the role of the
immune response and inflammation in AD pathogenesis.
However, the mechanism by which these variants increase
risk for AD remains unknown. Coding variants in other genes
in the TREM-gene family may also modify AD risk as is the
case for a common protective variant in TREML2 (Benitez
et al., 2014).
New AD Risk Genes: PLD3
Applying a family-based design to identify novel AD risk genes
revealed several rare, missense, and synonymous variants in
phospholipase D3 (PLD3) associated with AD risk (Cruchaga
et al., 2014). Whole-exome sequencing identified one variant in
PLD3 (PLD3 V232M; rs145999145), which segregated with
disease status in two of 14 independent NIA-LOAD families.
Follow-up studies in several case-control series demonstrated
that this variant is associated with a 2- to 3-fold increase in risk
for AD. Resequencing of PLD3 in over 4,000 AD cases and con-
trols revealed a significant excess of coding variants in cases
compared to controls in both European and African American
samples.
PLD3 is a nonclassical phospholipase. Little is known
regarding the function of PLD3 or its role in the brain. Previous
studies have reported a link between PLD1 and PLD2, classical
phospholipases, and APPmetabolism (Cai et al., 2006a, 2006b).
In cell models of APP processing, PLD3 also influences APP
metabolism such that overexpression leads to lower Ab levels,
while knockdown of PLD3 leads to increased levels of Ab
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elucidate the specific function of PLD3 in the brain and the path-
ogenic mechanism associated with the risk variants.
Disease Mechanisms Implicated by Studies of Genetic
Risk Factors for AD
Early-onset AD mutations in APP, PSEN1, and PSEN2 lead to
altered production or ratios of Ab isoforms in the brain, while
APOE influences Ab clearance and aggregation; both observa-
tions support the hypothesis that Ab levels are critical for disease
pathogenesis. GWASs have now identified polymorphisms in or
near more than 20 genes that are associated with AD risk
(Table 1). The identification of common variants that have small
effects on AD risk has created a broader picture of the processes
and pathways involved in AD risk including lipid metabolism, the
inflammatory response, and endocytosis (Figure 1). Whole-
genome/exome sequencing studies have also identified risk
alleles in TREM2 and PLD3. The identification of rare variants
in the population that have moderate to large effects on AD
risk will be most valuable in identifying pathways that are central
to disease pathogenesis. The majority of the genes recently
identified affect Ab production and clearance, highlighting the
importance of this pathway in AD pathogenesis.
Lipid Metabolism
APOE and several recent late-onset AD GWAS genes are
involved in lipid metabolism: CLU, ABCA7, and SORL1 (Harold
et al., 2009; Hollingworth et al., 2011; Lambert et al., 2009,
2013; Naj et al., 2011) (Table 1). APOE probably affects Abmeta-
bolism directly by binding to Ab or indirectly by binding to lipo-
protein receptors that play a role in Ab clearance (reviewed in
Holtzman et al., 2012). ABCA7may influence AD risk via its ability
to transfer cholesterol to APOE and modulate Ab levels or by
clearing Ab aggregates (Chan et al., 2008; Kim et al., 2013).
Clusterin (Apolipoprotein J) also plays a role in Ab clearance.
APOE- and Clusterin-deficient APP transgenic mice exhibit
earlier and more extensive Ab deposition than control mice (De-
Mattos et al., 2004). Genes involved in lipid metabolism share a
potential role in clearance of highly amyloidogenic Ab from the
brain. So polymorphisms in these genes that modify efficiency
of Ab clearance could have deleterious effects in the brain.
Immune Response
Neuroinflammation and dysregulation of the immune response is
a central feature of AD (reviewed in Holtzman et al., 2011).
Common variants have been identified in several genes that
are associated with late-onset AD in GWASs: CR1, CD33,
MS4A, CLU, ABCA7, EPHA1, HLA-DRB5-DRB1, and INPP5D
(Bertram et al., 2008; Harold et al., 2009; Hollingworth et al.,
2011; Lambert et al., 2009, 2013; Naj et al., 2011) (Table 1).
Rare coding variants were also identified in TREM2 in
sequencing studies of late-onset AD cohorts (Guerreiro et al.,
2013a; Jonsson et al., 2013). Elevated complement cascade
activity could exacerbate AD pathology; thus, individuals with
CR1 variants that dampen the complement response may be
at lower risk for developing AD pathology (Liu and Niu, 2009;
Shen et al., 2001). CD33 may play a role in Ab clearance and
other neuroinflammatory pathways mediated by microglia in
the brain (Griciuc et al., 2013). TREM2 may influence neurode-
generation, possibly through clearance of protein aggregatesor via neuroinflammatory mechanisms (Colonna, 2003). Interest-
ingly, TREM2, like APP, is cleaved by g-secretase (Wunderlich
et al., 2013). Extensive evidence from human studies and mouse
models demonstrates that amyloid plaques are surrounded by
activated immune cells. Interestingly, transcriptomics of unique
cell populations in the mouse brain reveal that one-third of
late-onset GWAS genes are differentially expressed at high
levels in microglia (B. Barres, personal communication). Thus,
polymorphisms in immune response genes that exacerbate or
dampen the immune system’s response to accumulating Ab
may contribute to AD pathogenesis.
Endocytosis
Endocytosis is critical for normal processing of APP, which is
central to AD pathogenesis. Furthermore, synaptic activity and
neurotransmitter release is disrupted in AD (reviewed in Holtz-
man et al., 2011). Genes associated with endocytosis and syn-
aptic function were identified in several late-onset AD GWAS:
BIN1, PICALM, CD2AP, EPHA1, SORL1, RIN3, MEF2C, and
MADD (Harold et al., 2009; Hollingworth et al., 2011; Lambert
et al., 2009; Lambert et al., 2013; Naj et al., 2011) (Table 1).
APP, Ab, and APOE are internalized through the endosomal-
lysosomal pathway, in which BIN1 plays a critical role (Chapuis
et al., 2013; McMahon et al., 1997). PICALM-mediated Ab
generation and clearance may influence accumulation of Ab in
AD brains (Xiao et al., 2012). CD2AP is required for synapse
formation (Dustin et al., 1998), where it associates with CBL,
endophilin, and synaptojanin. EPHA1 plays roles in cell and
axonal guidance and synaptic plasticity (Lai and Ip, 2009).
SORL1 directs APP to endocytic pathways for recycling (Ro-
gaeva et al., 2007) and plays an important role in Ab generation
(Schmidt et al., 2007; Spoelgen et al., 2006). Indeed, small mol-
ecules that increase the stability and function of the retromer
complex reduce the amount of APP in the endosomes and
reduce Ab levels, suggesting that this could be a possible thera-
peutic avenue (Mecozzi et al., 2014). In cell and animal models of
AD, synaptic activity alters Ab (Cirrito et al., 2005, 2008); thus,
polymorphisms in genes that influence synaptic function and
normal processing of APP and Ab are likely to contribute to AD
pathogenesis.
Tau
While all of the AD genes identified by linkage studies and the
majority of genes identified by GWASs and sequencing studies
have been implicated in pathways related to APP and Ab meta-
bolism, some genes are also implicated in taumetabolism. Tau is
the central component of neurofibrillary tangles, which are highly
predictive of AD progression. Recent CSF GWASs have demon-
strated that APOE genotype produces an Ab-independent effect
on CSF tau levels, suggesting that APOE could influence tau
accumulation in the brain (Cruchaga et al., 2013). Decreased
expression of the Drosophila ortholog of BIN1 is associated
with decreased tau-mediated toxicity in a Drosophila model
(Chapuis et al., 2013). Similarly, the Drosophila orthologs to
CD2AP, FERMT2, and CELF1 were identified as modifiers of
tau-mediated toxicity (Shulman et al., 2014). There is increasing
evidence that tau is released from the cell and that this release
may be modified by synaptic activity (Karch et al., 2012, 2013;
Pooler et al., 2013; Yamada et al., 2014). Coupled with in vitro
and in vivo evidence of spreading of tau aggregates, theseNeuron 83, July 2, 2014 ª2014 Elsevier Inc. 19
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alter synaptic function, such as BIN1, CD2AP, PTK2B, MEF2C,
NYAP1, and MADD, may influence tau release and spreading
of tau pathology in the brain (Table 1).
Cell-Type-Specific Expression of LOAD Risk Genes
Our understanding of the role that APP processing plays in AD
pathogenesis has been informed largely by the familial AD genes
APP, PSEN1, and PSEN2. For these genes, there is a clear link
between altered Ab production by neurons and development
of disease. However, with the identification of additional com-
mon risk loci by GWASs and rare risk variants by WES and
WGS, we are gaining a more complete picture of the important
role that supporting cells play in AD pathogenesis (Figure 1).
Many genes that fall within the GWAS loci are highly expressed
in microglia and astrocytes (Figure 1). In an unbiased approach,
we mined a gene expression data set from specific cell types
isolated frommouse brains, which included astrocytes, neurons,
oligodendrocytes, microglia, and endothelial cells (B. Barres,
personal communication). In searching LOAD risk genes identi-
fied by GWAS and sequencing methods, we found that many
of these genes were most highly expressed in cells other than
neurons. In Figure 1, we list genes based on the cell type in which
they are most highly expressed in the mouse brain. Considering
the expression pattern of these genes in the brain may be very
meaningful in determining the mechanisms underlying disease.
For example, clearance of Ab by microglia and astrocytes may
play a more important role in LOAD than Ab production by
neurons.
Future Directions for Genetic Studies
Substantial progress has been made during the last 5 years
toward understanding the genetic architecture of AD, because
of the technological advances in genotyping and sequencing
that have made it feasible to genotype or sequence thousands
of individuals. GWASs have now identified more than 20 loci
that influence risk for AD. It is clear from these studies that
with the exception of APOE, common risk alleles for AD have
modest effects on risk individually but they have pointed to a
number of important disease pathways. A recent study indi-
cates that common variants explain 33% of total phenotypic
variance. APOE alone explained 6% and other known markers
2%, meaning more than 25% of phenotypic variance remains
unexplained by known common markers (Ridge et al., 2013). It
is expected that studies using even larger sample sizes will iden-
tify additional loci, most likely with smaller effect sizes. Identifi-
cation of additional loci will probably implicate further biological
pathways in disease risk, but it is unlikely that GWAS SNPs will
be used to predict individual risk for AD. In other disorders
where even larger samples have been genotyped, more risk
loci have been identified, suggesting that there is some value
to continuing to increase the number of samples with GWAS
data. While very large sample sizes have been examined for
people of European descent, this is not true for other popula-
tions. Large GWASs in these populations may identify genes
not detected in Europeans. In addition, other AD-related pheno-
types including rate of progression of AD, rate of cognitive
decline, and age at onset of AD have yet to be examined in
the largest data sets.20 Neuron 83, July 2, 2014 ª2014 Elsevier Inc.An alternative approach to increasing sample size is to use
gene-based or pathway-based analyses to identify the genes,
that while not genome-wide significant are overrepresented
among the SNPs with low p values in GWASs. This approach
has identified additional significant genes that further implicate
immune regulation, energy metabolism, and protein degradation
in AD risk (Jones et al., 2010). Another approach has compared
GWAS data across related disorders to identify common under-
lying genes demonstrating a genetic link between cardiovascular
disease and AD risk (Liu et al., 2014; Moskvina et al., 2013). A
challenge for the field remains follow-up of the GWAS loci to
identify the specific functional alleles and the specific mecha-
nisms underlying the GWAS signals.
We anticipate that similar success in identifying novel genes
will be observed as large-scale sequencing projects begin to
yield results. Early studies, in small discovery data sets, have
already identified several promising genes that modify AD risk
(Cruchaga et al., 2014; Guerreiro et al., 2013a; Jonsson et al.,
2013). So far these studies have largely focused on whole-
exome sequencing and have identified coding variation that
alters risk for AD by as much as 2- to 3-fold. This has the advan-
tage of making functional follow-up of the genes identified
through sequencing substantially easier than those identified in
GWASs. Several groups are currently performing whole-exome
sequencing or whole-genome sequencing in unrelated AD cases
and controls and in families multiply-affected by AD. It is antici-
pated that whole-exome sequencing or whole-genome
sequencing will be available on more than 20 thousand well-
characterized samples before the end of 2014. Both the GWAS
data and the sequencing data will be available through public
repositories such as NIAGADS and dbGaP. Combining this
data with other large data sets such as transcriptomics from
human brain tissue or induced pluripotent stem cell-derived
neurons and glia will provide further insight into the disease path-
ways, and regulatory nodes within these pathways that may pro-
vide druggable targets for future therapies. An early application
of this integrative network-based approach used brain tissue
from over 1,600 AD cases and nondemented individuals to iden-
tify an immune- and microglia-specific module that is dominated
by genes involved in pathogen phagocytosis (Forabosco et al.,
2013; Zhang et al., 2013). This module contains TREM2
(identified by WES) but shows that TYROBP (a.k.a. DAP12,
which binds to TREM2) is a key regulator of the network and is
upregulated in AD brains. Mousemicroglia overexpressing intact
or truncated TYROBP revealed expression changes that
significantly overlapped the human brain TYROBP network.
Interestingly, LOAD GWAS genes MS4A4A, MS4A6A, and
CD33 were also identified in the module that contains TYROBP
(Zhang et al., 2013). The causal network structure was able
to predict response to gene perturbations and thus presents a
useful framework to test models of disease mechanisms under-
lying AD.
Using Genetics to Provide Insights into Clinical
Research
The AD field as a whole has struggled to move drugs and poten-
tial druggable targets from mouse models into effective thera-
pies. In part, this may be due to the fundamental study design
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et al., 2011; Moulder et al., 2013). The majority of Phase 3 clinical
trials have used individuals with mild to moderate dementia and
a clinical diagnosis of late-onset AD, which is known to be a het-
erogeneous disease. Recent studies have highlighted that many
people enrolled in these clinical trials were amyloid negative
based on neuroimaging data and therefore unlikely to respond
to an antiamyloid treatment (Vellas et al., 2013). A drug’s impact
on halting or slowing disease progression is hard to assess when
power is drastically reduced by the presence of non-AD cases
among the patients enrolled in the study. A second problem
with these trials has been that a drug that targets Ab may not
be effective in symptomatic AD cases because Ab deposition
occurs in the preclinical phase of the disease and thus reversal
of Ab deposition after clinical symptoms appear may have no
impact on disease progression. Identifying individuals with pre-
symptomatic disease would require large-scale screening in
most populations.
One way to address these issues is to focus trial design on
individuals who will develop AD, with a known age at onset
and disease progression. Dominantly inherited AD cases meet
these criteria since mutation carriers will all develop AD and
usually do so with an age at onset similar to that observed in their
parents and other family members. Second, because the muta-
tions in these families cause disease by increasing Ab produc-
tion, a therapy designed to remove Ab or inhibit Ab production
is directly targeting the disease mechanism. The Dominantly
Inherited Alzheimer Network (DIAN) was initiated 6 years ago
to recruit families that carry APP, PSEN1, and PSEN2mutations.
Observational studies in these families have demonstrated that
biomarker changes can occur 15–20 years prior to the expected
age at onset of AD (Fagan et al., 2014; Potter et al., 2013),
providing a large window of opportunity for presymptomatic
clinical trials. Two clinical trials in presymptomatic, biomarker-
positive mutation carriers have started within the last year.
The DIAN study is testing two anti-Ab antibodies while the
Alzheimer’s disease Prevention Initiative is testing a different
Ab monoclonal antibody in presymptomatic individuals from
the Colombian kindred carrying the PSEN1 E280A mutation.
Initial outcomes in these trials will be a change in fluid and imag-
ing biomarkers, with follow-up studies assessing clinical and
cognitive outcomes (Moulder et al., 2013). For the first time,
these clinical trials will provide a true test of the b-amyloid
cascade hypothesis, more than 20 years after the initial hypoth-
esis. This is perhaps fitting given that the hypothesis arose
around initial genetic discoveries in these and other families.
Conclusion
The identification of common and rare variants that contribute to
AD risk has provided many new opportunities to understand the
mechanisms underlying AD. GWASs and next-generation
sequencing studies have revealed genes that fall into several
common pathways that were previously known to be important
in AD pathogenesis: lipid metabolism, immune response, and
endocytosis/synaptic function. As whole-genome and whole-
exome sequencing studies in large data sets are completed,
many more genes will likely be added to this list. As we gain a
more complete picture of the genes and pathways dysregulatedin AD, we will be able to develop better, more targeted thera-
peutics.
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